L'elenco completo delle pubblicazioni del Laboratorio è disponibile sul sito della Biblioteca Medica 


Di seguito una selezione delle migliori pubblicazioni

  • Spatially resolved, high-dimensional transcriptomics sorts out the evolution of biphasic malignant pleural mesothelioma: new paradigms for immunotherapy. Torricelli F, Donati B, Reggiani F, Manicardi V, Piana S, Valli R, Lococo F, Ciarrocchi A. Mol Cancer. 2023 Jul 17;22(1):114. doi: 10.1186/s12943-023-01816-9.
  • Ex vivo mapping of enhancer networks that define the transcriptional program driving melanoma metastasis. Manicardi V, Gugnoni M, Sauta E, Donati B, Vitale E, Torricelli F, Manzotti G, Piana S, Longo C, Ghini F, Ciarrocchi A. Mol Oncol. 2023 Jul 6. doi: 10.1002/1878-0261.13485.
  • Long non-coding RNA mitophagy and ALK- anaplastic lymphoma associated transcript: a novel regulator of mitophagy in T cell lymphoma. Mularoni V, Donati B, Tameni A, Manicardi V, Reggiani F, Sauta E, Zanelli M, Tigano M, Vitale E, Torricelli F, Ascani S, Martino G, Inghirami G, Sanguedolce F, Ruffini A, Bavieri A, Luminari S, Pizzi M, Dei Tos AP, Fesce C, Neri A, Ciarrocchi A, Fragliasso V. Haematologica. 2023 Jun 29. doi: 10.3324/haematol.2022.282552.
  • Medullary Thyroid Carcinomas Classified According to the International Medullary Carcinoma Grading System and a Surveillance, Epidemiology, and End Results-Based Metastatic Risk Score: A Correlation With Genetic Profile and Angioinvasion. Torricelli F, Santandrea G, Botti C, Ragazzi M, Vezzani S, Frasoldati A, Ghidini A, Giordano D, Zanetti E, Rossi T, Nicoli D, Ciarrocchi A, Piana S. Mod Pathol. 2023 Jun 10;36(9):100244. doi: 10.1016/j.modpat.2023.100244.
  • An Innovative Drug Repurposing Approach to Restrain Endometrial Cancer Metastatization. Torricelli F, Sauta E, Manicardi V, Mandato VD, Palicelli A, Ciarrocchi A, Manzotti G. Cells. 2023 Mar 3;12(5):794. doi: 10.3390/cells12050794.  
  • Adding pieces to the puzzle of differentiated-to-anaplastic thyroid cancer evolution: the oncogene E2F7. Gugnoni M, Lorenzini E, Faria do Valle I, Remondini D, Castellani G, Torricelli F, Sauta E, Donati B, Ragazzi M, Ghini F, Piana S, Ciarrocchi A, Manzotti G. Cell Death Dis . 2023 Feb 10;14(2):99. doi: 10.1038/s41419-023-05603-8.
  • BETi enhance ATGL expression and its lipase activity to exert their antitumoral effects in triple-negative breast cancer (TNBC) cells. Rossi T, Zamponi R, Chirico M, Pisanu ME, Iorio E, Torricelli F, Gugnoni M, Ciarrocchi A, Pistoni M. J Exp Clin Cancer Res. 2023 Jan 6;42(1):7. doi: 10.1186/s13046-022-02571-3.
  • Activation of long non-coding RNA NEAT1 leads to survival advantage of multiple myeloma cells by supporting a positive regulatory loop with DNA repair proteins. Taiana E, Bandini C, Favasuli VK, Ronchetti D, Silvestris I, Puccio N, Todoerti K, Erratico S, Giannandrea D, Bolli N, Amodio N, Ciarrocchi A, Chiaramonte R, Torrente Y, Piva R, Neri A. Haematologica . 2023 Jan 1;108(1):219-233. doi: 10.3324/haematol.2022.281167.
  • KAP1 is a new non-genetic vulnerability of malignant pleural mesothelioma (MPM). Lorenzini E, Torricelli F, Zamponi R, Donati B, Manicardi V, Sauta E, Faria do Valle I, Reggiani F, Gugnoni M, Manzotti G, Fragliasso V, Vitale E, Piana S, Sancisi V, Ciarrocchi A.NAR Cancer. 2022 Jul 29;4(3):zcac024. doi: 10.1093/narcan/zcac024.
  • The multifaceted role of EGLN family prolyl hydroxylases in cancer: going beyond HIF regulation. Strocchi S, Reggiani F, Gobbi G, Ciarrocchi A, Sancisi V. Oncogene. 2022 Jul;41(29):3665-3679. doi: 10.1038/s41388-022-02378-8.
  • A multimodal integrative approach to model transcriptional addiction of thyroid cancer on RUNX2. Vitale E, Sauta E, Gugnoni M, Torricelli F, Manicardi V, Ciarrocchi A.Cancer Commun (Lond). 2022 Sep;42(9):892-896. doi: 10.1002/cac2.12292.   
  • OVOL2 impairs RHO GTPase signaling to restrain mitosis and aggressiveness of Anaplastic Thyroid Cancer. Gugnoni M, Manzotti G, Vitale E, Sauta E, Torricelli F, Reggiani F, Pistoni M, Piana S, Ciarrocchi A. J Exp Clin Cancer Res. 2022 Mar 25;41(1):108. doi: 10.1186/s13046-022-02316-2.
  • No Need to Stick Together to Be Connected: Multiple Types of Enhancers' Networking. Vitale E, Gugnoni M, Ciarrocchi A.Cancers (Basel). 2021 Oct 16;13(20):5201. doi: 10.3390/cancers13205201.  
  • CSNK1A1, KDM2A, and LTB4R2 Are New Druggable Vulnerabilities in Lung Cancer. Sauta E, Reggiani F, Torricelli F, Zanetti E, Tagliavini E, Santandrea G, Gobbi G, Strocchi S, Paci M, Damia G, Bellazzi R, Ambrosetti D, Ciarrocchi A, Sancisi V. Cancers (Basel). 2021 Jul 12;13(14):3477. doi: 10.3390/cancers13143477. 
  • An integrative functional genomics approach reveals EGLN1 as a novel therapeutic target in KRAS mutated lung adenocarcinoma. Reggiani F, Sauta E, Torricelli F, Zanetti E, Tagliavini E, Santandrea G, Gobbi G, Damia G, Bellazzi R, Ambrosetti D, Ciarrocchi A, Sancisi V. Mol Cancer . 2021 Apr 6;20(1):63. doi: 10.1186/s12943-021-01357-z.
  • Long Noncoding RNA NEAT1 Acts as a Molecular Switch for BRD4 Transcriptional Activity and Mediates Repression of BRD4/WDR5 Target Genes. Pistoni M, Rossi T, Donati B, Torricelli F, Polano M, Ciarrocchi A. Mol Cancer Res. 2021 May;19(5):799-811. doi: 10.1158/1541-7786.MCR-20-0324.
  • The DNA-helicase HELLS drives ALK- ALCL proliferation by the transcriptional control of a cytokinesis-related program. Tameni A, Sauta E, Mularoni V, Torricelli F, Manzotti G, Inghirami G, Bellazzi R, Fragliasso V, Ciarrocchi A. Cell Death Dis. 2021 Jan 27;12(1):130. doi: 10.1038/s41419-021-03425-0.
  • YAP and TAZ Are Not Identical Twins. Reggiani F, Gobbi G, Ciarrocchi A, Sancisi V. Trends Biochem Sci. 2021 Feb;46(2):154-168. doi: 10.1016/j.tibs.2020.08.012.
  • Deep Sequencing Analysis Identified a Specific Subset of Mutations Distinctive of Biphasic Malignant Pleural Mesothelioma. Torricelli F, Lococo F, Di Stefano TS, Lorenzini E, Piana S, Valli R, Rena O, Veronesi G, Billè A, Ciarrocchi A. Cancers (Basel). 2020 Aug 29;12(9):2454. doi: 10.3390/cancers12092454.
  • Linc00941 Is a Novel Transforming Growth Factor β Target That Primes Papillary Thyroid Cancer Metastatic Behavior by Regulating the Expression of Cadherin 6. Gugnoni M, Manicardi V, Torricelli F, Sauta E, Bellazzi R, Manzotti G, Vitale E, de Biase D, Piana S, Ciarrocchi A.Thyroid. 2021 Feb;31(2):247-263. doi: 10.1089/thy.2020.0001.  
  • Genomic analysis in short- and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy. Torricelli F, Saxena A, Nuamah R, Neat M, Harling L, Ng W, Spicer J, Ciarrocchi A, Bille A. Eur J Cancer . 2020 Jun;132:104-111. doi: 10.1016/j.ejca.2020.03.002.
  • The novel lncRNA BlackMamba controls the neoplastic phenotype of ALK- anaplastic large cell lymphoma by regulating the DNA helicase HELLS. Fragliasso V, Verma A, Manzotti G, Tameni A, Bareja R, Heavican TB, Iqbal J, Wang R, Fiore D, Mularoni V, Chan WC, Lhoumaud P, Skok J, Zanetti E, Merli F, Ciarrocchi A, Elemento O, Inghirami G. Leukemia. 2020 Nov;34(11):2964-2980. doi: 10.1038/s41375-020-0754-8.
  • Multiple roles and context-specific mechanisms underlying YAP and TAZ-mediated resistance to anti-cancer therapy. Reggiani F, Gobbi G, Ciarrocchi A, Ambrosetti DC, Sancisi V. Biochim Biophys Acta Rev Cancer . 2020 Jan;1873(1):188341. doi: 10.1016/j.bbcan.2020.188341. 
  • Approaches to Tumor Classification in Pulmonary Sarcomatoid Carcinoma. Baldovini C, Rossi G, Ciarrocchi A. Lung Cancer (Auckl). 2019 Dec 5;10:131-149. doi: 10.2147/LCTT.S186779
  • A Gene Expression-based Model to Predict Metabolic Response After Two Courses of ABVD in Hodgkin Lymphoma Patients. Luminari S, Donati B, Casali M, Valli R, Santi R, Puccini B, Kovalchuk S, Ruffini A, Fama A, Berti V, Fragliasso V, Zanelli M, Vergoni F, Versari A, Rigacci L, Merli F, Ciarrocchi A. Clin Cancer Res. 2020 Jan 15;26(2):373-383. doi: 10.1158/1078-0432.CCR-19-2356.
  • RAIN Is a Novel Enhancer-Associated lncRNA That Controls RUNX2 Expression and Promotes Breast and Thyroid Cancer. Rossi T, Pistoni M, Sancisi V, Gobbi G, Torricelli F, Donati B, Ribisi S, Gugnoni M, Ciarrocchi A. Mol Cancer Res. 2020 Jan;18(1):140-152. doi: 10.1158/1541-7786.MCR-19-0564.  
  • The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells. Gobbi G, Donati B, Do Valle IF, Reggiani F, Torricelli F, Remondini D, Castellani G, Ambrosetti DC, Ciarrocchi A, Sancisi V. Oncogene. 2019 Oct;38(42):6801-6817. doi: 10.1038/s41388-019-0924-1
  • HDACs control RUNX2 expression in cancer cells through redundant and cell context-dependent mechanisms. Manzotti G, Torricelli F, Donati B, Sancisi V, Gugnoni M, Ciarrocchi A. J Exp Clin Cancer Res. 2019 Aug 8;38(1):346. doi: 10.1186/s13046-019-1350-5.
  • Telomerase and Telomeres Biology in Thyroid Cancer. Donati B, Ciarrocchi A. Int J Mol Sci. 2019 Jun 13;20(12):2887. doi: 10.3390/ijms20122887.
  • Long Noncoding RNA and Epithelial Mesenchymal Transition in Cancer. Gugnoni M, Ciarrocchi A.Int J Mol Sci. 2019 Apr 18;20(8):1924. doi: 10.3390/ijms20081924.
  • Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy. Manzotti G, Ciarrocchi A, Sancisi V. Cancers (Basel). 2019 Mar 5;11(3):304. doi: 10.3390/cancers11030304.
  • An Epithelial-to-Mesenchymal Transcriptional Switch Triggers Evolution of Pulmonary Sarcomatoid Carcinoma (PSC) and Identifies Dasatinib as New Therapeutic Option. Manzotti G, Torricelli F, Benedetta D, Lococo F, Sancisi V, Rossi G, Piana S, Ciarrocchi A. Clin Cancer Res. 2019 Apr 1;25(7):2348-2360. doi: 10.1158/1078-0432.CCR-18-2364. Donati B, Lorenzini E, Ciarrocchi A. Mol Cancer . 2018 Nov 22;17(1):164. doi: 10.1186/s12943-018-0915-9.
  • The bHLH transcription factor DEC1 promotes thyroid cancer aggressiveness by the interplay with NOTCH1. Gallo C, Fragliasso V, Donati B, Torricelli F, Tameni A, Piana S, Ciarrocchi A.Cell Death Dis. 2018 Aug 29;9(9):871. doi: 10.1038/s41419-018-0933-y.
  • The long non-coding RNA TAZ-AS202 promotes lung cancer progression via regulation of the E2F1 transcription factor and activation of Ephrin signaling. Gobbi G, Grieco A, Torricelli F, Sauta E, Santandrea G, Zanetti E, Fantini V, Reggiani F, Strocchi S, Paci M, Vohra M, Saladi SV, Ambrosetti DC, Ciarrocchi A, Sancisi V. Cell Death Dis. 2023 Nov 18;14(11):752. doi: 10.1038/s41419-023-06277-y.
  • Spatial Distribution of Immune Cells Drives Resistance to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Donati B, Reggiani F, Torricelli F, Santandrea G, Rossi T, Bisagni A, Gasparini E, Neri A, Cortesi L, Ferrari G, Bisagni G, Ragazzi M, Ciarrocchi A.
    Cancer Immunol Res. 2024 Jan 3;12(1):120-134. doi: 10.1158/2326-6066.CIR-23-0076.

Ultimo aggiornamento: 25/01/24